

BIBLIOGRAPHY

1. Neharkar VS, Gaikwad KG. Hepatoprotective activity of *Cassia alata* (linn) leaves against paracetamol induced hepatic injury in rats. Res J Phar Biol Chem. Sci. 2011; 2(1): 783-88.
2. Mohan H. Textbook of Pathology. 4th ed. New Delhi: Jaypee brother's medical publisher; 2002.
3. Francis JB, Thorat PK, Lonkar AD. Toxicity of *Gyandropsis pentaphylla* DC extracts against microbials and its phytochemical profile. Ethnobotanical leaflets.2008; 12:320-36.
4. Rajesh MG, Latha MS. Preliminary evaluation of the anti hepatotoxic activity of kamilari, a polyherbal formulation. J Ethnopharmacol 2004; 91: 99-104.
5. Ramachandran R , Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol 2009; 62(6):481-92.
6. Klaassen,CD, Watkins,JB. (Editors). Casarett and Doull's Essentials of Toxicology. New York: McGraw-Hill; Health professional division: 2003.
7. Kim HS, Lim HK, Chung MW, Kim YC. Antihepatotoxic activity of bergenin, the major constituent of *Mallotus japonicus*, on carbon tetrachloride-intoxicated hepatocytes. J of Ethnopharmacol. 2000; 69(1): 79-83.
8. Jain A, Soni M, Deb L, Jain A, Rout SP, Gupta VB. Antioxidant and hepatoprotective activity of ethanolic and aqueous extract of *Momordica dioica* Roxb, Leaves. J Ethanopharmacol. 2008; 115 (1): 61-66.

9. Rojkind M, Giambrone MA, Biempica L. Collagen types in normal and cirrhotic liver. *Gastroenterology*. 1979; 76: 710-5.
10. Benedetti A, Ferrali M, Cheili E. A study of the relationship between carbon tetrachloride-induced lipid peroxidation and liver damage in rats pretreated with Vitamin E. *Chem Biol Interact*. 1974; 9: 117–200.
11. Camps J, Bargallo T, Gimenez. A relationship between hepatic lipid peroxidation and fibrogenesis in carbon tetrachloride-treated rats: effects of zinc administration. *Clin Sci (Lond)*. 1992; 83: 695–700.
12. Rubin E, Farber JL. The liver and biliary system In: *Pathology*. 4th ed. Philadelphia: JB Lipincott Company; 1988.
13. Recknagel RO. A new direction in the study of carbon tetrachloride hepatotoxicity. *Life Sci*. 1983; 33: 401–08.
14. Weissmann G. The role of lysosomes in inflammation and diseases. *Ann Rev Med*. 1967; 18: 97–112.
15. Aronson AA. *Glycoproteins*. 4th ed. Amsterdam: Elsevier; 1972.
16. Suzuki S, Nakamura N, Koizumi T. The heterogeneity of dermatan sulphate and heparan sulphate in rat liver and a shift in the glycosaminoglycan contents in carbon tetrachloride damaged liver. *Biochem Biophys Acta*. 1976; 428: 166–81.
17. Murata K, Onuma H. Compositional changes of glycosaminoglycans and collagen molecules in fibrotic process in human liver. *Coll Relat Dis* 1983; 3: 72–81.

18. Bravo J, Heath JK. Receptor recognition by gp130 cytokines. *EMBO J* 2000; 19: 2399-411.
19. Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. *Endocr Rev* 1989; 10: 68-91.
20. Daughaday WH. Growth hormone axis overview: somatomedin hypothesis. *Pediatr Nephrol*. 2000; 14: 537-40.
21. Mappayyanavarmath S.S, Patil P.A. The influence of tricyclic antidepressants on resutured incision and dead space wound healing in albino rats. *Ind J Pharmacol* 1999; 31: 290-93.
22. Youn YK, Suh GJ, Jung SE, Oh SK, Demling R. Recombinant human growth hormone decreases lung and liver tissue lipid peroxidation and increases antioxidant activity after thermal injury in rats. *J Burn care Rehabil*. 1988; 19(6): 542-8.
23. Randle LE, Sathish JG, Kitteringham NR, Macdonald I, Williams DP, Park BK. α 1- Adrenoceptor antagonists prevent paracetamol induced hepatotoxicity in mice, *British J Pharmacol*. 2008; 153: 820-30.
24. Neri M, Cerretani D, Fiaschi AI, Laghi PF, Lazzerini PE, Maffione AB. Correlation between cardiac oxidative stress and myocardial pathology due to acute and chronic norepinephrine administration in rats. *J Cell Mol Med*. 2007; 11 : 156-170.

25. Oben JA, Roskams T, Yang S, Lin H, Sinelli N, Li Z, Torbenson M, Huang J, Guarino P, Kafrouni M, Diehl AM. Sympathetic nervous system inhibition increases hepatic progenitors and reduces liver injury. *Hepatology*. 2003; 38(3): 664- 73.
26. Martin JB, Brazeau P, Tannenbaum GS, Willoughby JO, Epelbaum J, Terry LC. Neuroendocrine organization of growth hormone regulation. *Res Publ Assoc Res Nerv Ment Dis*. 1978;56:329-57.
27. Martin JB. Functions of central nervous system neurotransmitters in regulation of growth hormone secretion. *Fed Proc*. 1980; 39:2902-06.
28. Omerovic E, Bollano E, Mobini R, Kujacic V, Madhu B, Soussi. Growth hormone improves bioenergetics and decreases catecholamines in postinfarct rat hearts. *Endocrinology*. 2000; 141: 4592-99.
29. Philipson JD. Natural products as a basis for new drugs. *Trends Pharmacol Sci*. 1989; 1: 36-38.
30. Ojewole JA. Analgesic, antiinflammatory and hypoglycemic effects of rhus chirindensis (Baker F). (Anacardiaceae) stem bark aqueous extract in mice and rat. *J Ethanopharmacol* 2007; 113:338-45.
31. Malesev D, Kuntic V. Investigation of metal–flavonoid chelates and determination of flavonoids via metal–flavonoid complexing reactions. *J Serb Chem Soc* 2007; 72: 921–39.
32. Alan L. Miller ND. Antioxidant Flavonoids: Structure, Function and Clinical Usage *Alternative Medicine Review* 1996; 1 (2): 103–11.

33. Nitin Dixit, Sanjula Baboota, Kanchan Kohli, S Ahmad, Javed Ali. Silymarin: A review of pharmacological aspects and bioavailability enhancement approaches. *Ind J Pharmacol.* 2007; 39(4): 172-9.
34. <http://www.thorne.com/altmedrev/.fulltext/3/2/140.pdf>. *Alternative Medicine Review _Volume 3, Number 2 _1998.*
35. Beibei F, Jing X, Zhaodong L, Xianglin S, Bing-HJ, Jing F. Chrysin inhibits expression of hypoxia-inducible factor-1A through reducing hypoxia-inducible factor-1A stability and inhibiting its protein synthesis. *Molecular cancer Therapeutics.* 2007; 6(1): 220-6.
36. Premila NS, Wilfred G, Banumathi R. Does oxidative protein damage play a role in pathogenesis of carbon tetra chloride- induced liver injury in the rats. *Biochemica et Biophysica Acta.* 1997; 1362: 169-76.
37. Tortora GJ, Anagnostakos NP. *Principles of Anatomy and Physiology.* 9th ed. New York: Harper & Row publishers; 2000.
38. Stine KE and Brown TM. *Principal of Toxicology.* 2nd ed. London: CRC Lewis Publication; 1996.
39. Premila A. Lysosomal enzyme activity during development of carbon tetrachloride induced cirrhosis in rats. *Indian J Physiol Pharmacol.* 2004; 48 (2): 206–12
40. Bennett PN, Brown MJ. *Clinical Pharmacology.* 9th ed. Spain: Library of Congress cataloging in Pub. Data; 2003.

41. Schiff ER, Sorrell MF, Maddary WC. Diseases of the Liver. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2007.
42. Christina AJ, Saraswathy GR, Robert SJ, Kothai R, Chidambaranathan N, Nalini G, Therasal RL. Inhibition of CCl₄ - induced liver fibrosis by Piper longum linn. *Phytomedicine*. 2006; 13: 196-98.
43. Deodhare SG. General Pathology and Pathology of systems. 6th ed. Mumbai: Popular prakashan Pvt Ltd; 2002.
44. Schiff L, Schiff ER. Diseases of the liver. 7th ed. Philadelphia: Lippincott company; 1993.
45. Cotran RS, Vinay and Collins T. The Liver and Biliary tract pathologic basis of disease. 6th ed. India: W.B. Saunders Company; 1999.
46. Sherlock S, Dooly J. Diseases of the Liver and Biliary system. 11th ed. Hong Kong: Blackwell publication; 2002.
47. Friedman SL. Hepatic fibrosis overview. *Toxicology*. 2008; 254: 120-29.
48. Patel RB, Raval JD. Hepatoprotective effect of Indian Medicinal Plants – Part I. *Indian Drugs* 1998; 25(6): 224-28.
49. Kissane JM. Anderson's Pathology. 9th ed. Toronto: Mosby Company; 1990.
50. Schiff ER, Sorrell MF, Maddary WC. Schiff's Diseases of the Liver. 9th ed. Philadelphia: PA Lippincott, Williams & Wilkins; 2003.
51. Keith G, Tolman MD, Robert R. Liver function. 3rd ed. Philadelphia: Saunders Company; 1999.

52. Thabrew I, Ayling RM. Biochemistry for Clinical medicine. London: Green wich Medical Media Ltd; 2001.
53. Paul Saftig. Lysosomes. New York: Springer science and Business Media; 2005.
54. Sembulingam K, Sembulingam P. Essentials of Medical Physiology. 4th ed. New Delhi: Jaypee Brothers Medical Publishers Pvt Ltd; 2006.
55. Bruce alberts, Johnson A, Lewis J. Molecular Bilogy of Cell. 4th ed. New York: 2002.Garland science 29 west; 2002.
56. Rege N, Dahanukar S and Karandikar SM. Hepatoprotective effect of Tinospora Cardifolia against CCl₄ induced liver damage. Indian Drugs 1984; 21: 544-55.
57. Doreswamy R, Sharma D. Plant Drug for Liver Disorder Management. Indian Drugs 1995; 32: 139-54.
58. Derek GD, Wight. Liver, Biliary Tract and Exocrine Pancreas Systemic Pathology. 3rd ed. New York: Churchill Livingstone Publishers; 1994.
59. Janakat S, Al-Merie H. Optimization of the dose and route of injection, and characterization of the time course of carbon-tetrachloride-induced hepatotoxicity in rat. J Pharmacol Toxicol Methods 2002; 48: 41-44.
60. Zimmerman HJ. Effects of various agents in Hepatotoxicity. New York: Appleton century Craft; 1978.
61. Daniels ME. Lilly's Humatrope Experience. Nature Biotechnology 1992; 10: 792-812.

62. Joel Houglum J, Harrelson, Gary L. Principles of Pharmacology for Athletic Trainers. Portland: Slack Inc; 2005.
63. Bartholomew EF, Frederic M, Nath JL. Fundamentals of Anatomy and Physiology, New Jersey: Pearson Education Inc; 2009.
64. Lin-Su K, Wajnrajch MP. Growth Hormone Releasing Hormone (GHRH) and the GHRH Receptor. Rev Endocr Metab Disord 2002; 3 (4): 313–23.
65. Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts GH, Morgan DG, Ghatei MA, Bloom SR. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000; 141 (11): 4325-28.
66. Meinhardt UJ, Ho KK. Modulation of growth hormone action by sex steroids. Clin Endocrinol 2006; 65 (4): 413-22.
67. Low LC. Growth hormone-releasing hormone: clinical studies and therapeutic aspects. Neuroendocrinology. 1991; 53 Suppl 1: 37–40.
68. Alba-Roth J, Müller OA, Schopohl J, von Werder K. Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion. J Clin Endocrinol Metab. 1988; 67 (6): 1186–89.
69. Van Cauter E, Latta F, Nedeltcheva A, Spiegel K, Leproult R, Vandenbril C, Weiss R, Mockel J, Legros JJ, Copinschi G. Reciprocal interactions between the GH axis and sleep. Growth Horm IGF Res. 2004; 14 Suppl A: 10–17.

70. Norrelund H. The metabolic role of growth hormone in humans with particular reference to fasting. *Growth Horm IGF Res.* 2005; 15 (2): 95–122.
71. Kanaley JA, Weltman JY, Veldhuis JD, Rogol AD, Hartman MI, Weltman A. Human growth hormone response to repeated bouts of aerobic exercise. *J Appl Physiol.* 1997; 83 (5): 1756–61.
72. Guillemin R, Gerich JE. Somatostatin: physiological and clinical significance. *Annu Rev Med* 1976; 27: 379–88.
73. Allen DB. Growth suppression by glucocorticoid therapy. *Endocrinol Metab Clin North Am.* 1996; 25 (3): 699–17.
74. Scarth JP. Modulation of the growth hormone-insulin-like growth factor (GH-IGF) axis by pharmaceutical, nutraceutical and environmental xenobiotics: an emerging role for xenobiotic-metabolizing enzymes and the transcription factors regulating their expression. A review. *Xenobiotica.* 2006; 36 (2-3): 119–218.
75. Natelson BH, Holaday J, Meyerhoff J, Stokes PE. Temporal changes in growth hormone, cortisol, and glucose: relation to light onset and behavior. *Am J Physiol.* 1975; 229 (2): 409–15.
76. Takahashi Y, Kipnis D, Daughaday W. Growth hormone secretion during sleep. *J Clin Invest.* 1968; 47 (9): 2079–90.
77. Mehta, Ameeta, Hindmarsh, Peter. The use of somatropin (recombinant growth hormone) in children of short stature. *Pediatric Drugs.* 2002; 4: 37-47.

78. Nindl BC, Hymer WC, Deaver DR, Kraemer WJ. Growth hormone pulsatility profile characteristics following acute heavy resistance exercise. *J Appl Physiol.* 2001; 91 (1): 163–72.
79. Juul A, Jorgensen JO, Christiansen JS, Müller J, Skakkeboek NE. Metabolic effects of GH: a rationale for continued GH treatment of GH-deficient adults after cessation of linear growth. *Horm Res.* 1995; 44 Suppl 3: 64–72.
80. Gardner, David G, Shoback, Dolores. 8th ed. New York: Greenspan's Basic and Clinical Endocrinology. McGraw-Hill Medical; 2007.
81. Mangnall D, Bird NC, Majeed AW. The molecular physiology of liver regeneration following partial hepatectomy. *Liver Int.* 2003; 23:124–38
82. Lambotte L, Saliez A, Triest S, Tagliaferri EM, Barker AP, Baranski AG. Control of rate and extent of the proliferative response after partial hepatectomy. *Am J Physiol.* 1997; 273: 905–12.
83. Bucher NL. Regeneration of mammalian liver. *Int Rev Cytol.* 1963; 15:245–300.
84. Fausto N, Laird AD, Webber EM. Liver regeneration II. Role of growth factors and cytokines in hepatic regeneration. *FASEB J.* 1995; 9:1527–36.
85. Michalopoulos GK, DeFrances MC. Liver regeneration. *Science* 1997; 276: 60–66.
86. Yamada Y, Kirillova I, Peschon JJ, Fausto N. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. *Proc Natl Acad Sci. USA,*1997; 94:1441-46.

87. Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V, Taub R. Liver failure and defective hepatocyte regeneration in interleukin- 6-deficient mice. *Science*. 1996; 274:1379–83.
88. Michalopoulos GK. Control mechanisms of liver regeneration. *J Gastroenterol*. 1994; 29(Suppl 7): 23–29.
89. Fausto N, Campbell JS. The role of hepatocytes and oval cells in liver regeneration and repopulation. *Mech Dev* 2003; 120:117–30.
90. Jones DE, Tran-Patterson R, Cui DM, Davin D, Estell KP, Miller DM. Epidermal growth factor secreted from the salivary gland is necessary for liver regeneration. *Am J Physiol*. 1995; 268:872– 78
91. Li W, Liang X, Kellendonk C, Poli V, Taub R. STAT₃ contributes to the mitogenic response of hepatocytes during liver regeneration. *J Biol Chem*. 2002; 277: 28411–17
92. Behrens A, Sibilias M, David JP, Mohle-Steinlein U, Tronche F, Schutz G. Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver. *EMBO J*. 2002; 21:1782–90.
93. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. *Endocr Rev*. 1997; 18:801–31.
94. Yakar S, Liu JL, Le Roith D. The growth hormone/insulin-like growth factor-I system: implications for organ growth and development. *Pediatr Nephrol*. 2000; 14:544–49.

95. McElduff A, Poronnik P, Baxter RC, Williams P. A comparison of the insulin and insulin-like growth factor I receptors from rat brain and liver. *Endocrinology*. 1988; 122:1933-39.
96. Lamas E, Zindy F, Seurin D, Guguen-Guillouzo C, Brechot C. Expression of insulin-like growth factor II and receptors for insulin-like growth factor II, insulin-like growth factor I and insulin in isolated and cultured rat hepatocytes. *Hepatology*. 1991; 13:936-40.
97. Zindy F, Lamas E, Schmidt S, Kirn A, Brechot C. Expression of insulin like growth factor II (IGF-II) and IGF-II, IGF-I and insulin receptors mRNAs in isolated non-parenchymal rat liver cells. *J Hepatol*. 1992; 14:30-34.
98. Mohn KL, Melby AE, Tewari DS, Laz TM, Taub R. The gene encoding rat insulin like growth factor-binding protein 1 is rapidly and highly induced in regenerating liver. *Mol Cell Biol*. 1991; 11:1393-401.
99. Leu JJ, Crissey MA, Craig LE, Taub R. Impaired hepatocyte DNA synthetic response posthepatectomy in insulin-like growth factor binding protein 1-deficient mice with defects in C/EBP and mitogen-activated protein kinase/ extracellular signal-regulated kinase regulation. *Mol Cell Biol*. 2003; 23:1251-59.
100. Leu JJ, Crissey MA, Taub R. Massive hepatic apoptosis associated with TGF-1 activation after Fas ligand treatment of IGF binding protein-1-deficient mice. *J Clin Invest*. 2003; 111:129-39.
101. Thompson BJL, Shang CA, Waters M. Identification of genes induced by growth hormone in rat liver using cDNA arrays. *Endocrinology*. 2000; 141:4321-24.

102. Rubin RA, O'Keefe EJ, Earp HS. Alteration of epidermal growth factor dependent phosphorylation during rat liver regeneration. *Proc Natl Acad Sci.* 1982; 79:776-80.
103. Toshimasa Yamauchi, Kohjiro Ueki, Kazuyuki Tobe, Hiroyuki Tamemoto, Nobuo Sekine, Mitsufumi Wada. Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone. *Nature.* 1997; 390: 91–96.
104. Ingleton PM, Rodgers GR, Faulkner M. The pituitary in cirrhosis: ultrastructure, growth hormone, and prolactin concentrations. *Exp Mol Pathol.* 1992; 56(2): 119-31.
105. Okada T, Uetsuka K, Yamauchi H, Tani Y, Endo K., Nakayama H, Doi K. Effects of exogenous growth hormone (GH) - treatment on CCl₄ induced acute liver injury in GH-deficient mini rats. *J Toxicol Pathol.* 2003; 16: 49-7.
106. Rovensky J, Ferencikova J, Vigas M, Lukac P. Effect of growth hormone on the activity of some lysosomal enzymes in neutrophilic polymorphonuclear leukocytes of hypopituitary dwarfs. *Int J Tissue React.* 1985; 7(2): 153-59.
107. [http://en.wikipedia.org/wiki/Catecholamines\(Catecholamine\)](http://en.wikipedia.org/wiki/Catecholamines(Catecholamine))
108. Anne Waugh, Allison Grant. *Ross and Wilson Anatomy and Physiology.* 10th ed. Churchill Livingstone, Elsevier; 2006.
109. Purves, Dale, McNamara, Leonard E. White. *Neuroscience.* 4th ed. Massachusetts: Sinauer Associates; 2008.

110. Joh TH, Hwang O. Dopamine beta-hydroxylase: biochemistry and molecular biology. New York: Annals of New York the Academy of Sciences; 1987: 493: 342-50.
111. Berthoud HR, Neuhuber WL. Functional and chemical anatomy of the afferent vagal system. *Auton Neurosci* 2000; 85:1-17.
112. Fausto N. Liver regeneration. *J Hepatol.* 2000; 32 (1 suppl): 19-31.
113. Jungermann K, Stumpel F. Role of hepatic, intrahepatic and hepatoenteral nerves in the regulation of carbohydrate metabolism and hemodynamics of the liver and intestine. *Hepatogastroenterology* 1999; 46(suppl 2):1414-17.
114. Rangari M, Sinha S, Kapoor D, Mohan JC, Sarin SK. Prevalence of autonomic dysfunction in cirrhotic and noncirrhotic portal hypertension. *Am J Gastroenterol.* 2002; 97: 707-13.
115. Hendrickse MT, Thuluvath PJ, Triger DR. Natural history of autonomic neuropathy in chronic liver disease. *Lancet.* 1992; 339:1462-64.
116. Dillon JF, Plevris JN, Nolan J, Ewing DJ, Neilson JM, Bouchier IA, Hayes PC. Autonomic function in cirrhosis assessed by cardiovascular reflex tests and 24-hour heart rate variability. *Am J Gastroenterol.* 1994; 89:1544-47
117. Miyajima H, Nomura M, Muguruma N, Okahisa T, Shibata H, Okamura S, Honda H, Shimizu I, Harada M, Saito K, Nakaya Y, Ito S. Relationship among gastric motility, autonomic activity, and portal hemodynamics in patients with liver cirrhosis. *J Gastroenterol Hepatol.* 2001; 16:647-59.

118. Pozzi M, Grassi G, Redaelli E, Dell'oro R, Ratti L, Redaelli A, Foglia G, Di Lelio A, Mancia G. Patterns of regional sympathetic nerve traffic in preascitic and ascitic cirrhosis. *Hepatology*. 2001; 34:1113-18.
119. Brody TM, Calvert DN., Schneider A.F. Alteration of carbon tetrachloride-induced pathologic changes in the rat by spinal transaction, adrenalectomy and adrenergic blocking agents. *J Pharmacol Exp Ther*. 1961; 131: 341-45.
120. Calvert TM, Brody T.M. Role of the sympathetic nervous system in CCl₄ hepatotoxicity. *Am J Physiol* 1960; 198(669): 669-76.
121. Brody TM, Calvert DN. Release of catecholamines from the adrenal medulla by CCl₄. *Am J Physiol* 1960; 198(682): 682-85.
122. Sverrisdottir YB, Mikael Elam, Hans Herlitz, Bengt-Ake Bengtsson, Gudmundur Johannsson. Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency. *J Clin Endocrinol Metab*. 1998; 83:1881-85.
123. Watanabe CMH, Siegfried Wolfram, Peter Ader, Gerald Rimbach, Lester Packer, John J. Maguire, Peter G. Schultz, Kishorchandra Gohil. The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba. *Proc Natl Acad Sci*. 2001; 98(12): 6577-80.
124. Luper S. A review of plants used in the treatment of liver disease: Part 1. *Altern Med Rev*. 1998; 3:410-21.
125. Pepping J. Milk thistle: *Silybum marianum*. *Am J Health Syst Pharm*. 1999; 56:1195-97.

126. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. *Drugs*. 2001; 61:2035-63.
127. Bisset N. In: *Herbal Drugs and Pharmaceuticals*. London: CRC Press; 1994.
128. Gruenwald J, Brendler T, Jaenicke C. *PDR for Herbal Medicines*. New Jersey: Medical Economics Company, Inc. Montvale; 1998.
129. Miller AL. Antioxidant flavonoids: structure, function and clinical usage. *Altern Med Rev*. 1996;1:103-11.
130. Walle T, Otake Y, Brubaker JA, Walle UK, Halushka PV. Disposition and metabolism of the flavonoid chrysin in normal volunteers. *Br J Clin Pharmacol*. 2001; 51 (2): 143–6.
131. Woo KJ, Jeong YJ, Inoue H, Park JW, Kwon TK. Chrysin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression through the inhibition of nuclear factor for IL-6 (NF-IL6) DNA-binding activity. *FEBS Lett*. 2005; 579 (3): 705–11.
132. Brown E, Hurd NS, McCall S, Ceremuga TE. Evaluation of the anxiolytic effects of chrysin, a *Passiflora incarnata* extract, in the laboratory rat. *AANA J*. 2007;75 (5): 333–7.
133. Wolfman C, Viola H, Paladini A, Dajas F, Medina JH. Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from *Passiflora coerulea*. *Pharmacol Biochem Behav*. 1994; 47 (1): 1–4.

134. Balch, Phyllis A. Prescription for herbal healing. An Easy-to-Use A-Z Reference to hundreds of common disorders and their herbal remedies. New York: Avery; 2002.
135. OECD Acute Oral Toxicity-Acute Toxic Class Method, guideline 423, OECD guideline for testing of chemicals. Organization for Economic Co-Operation and Development, Paris; Dec 2001.
136. Abraham P. Lysosomal enzyme activity during development of carbon tetrachloride induced cirrhosis in rats. *Ind J Physiol Pharmacol.* 2004; 48(2): 206-12.
137. McLean EK, McLean AEM, Sutton PM. Instant cirrhosis: a improved method for producing cirrhosis of the liver in rats by the simultaneous administration of carbon tetrachloride and phenobarbitone. *Br J Exp Pathol.* 1969; 50: 502–06.
138. Kyaw A, Aung T, Htut T. Lysosomal enzyme activities in normals and in patients with chronic liver diseases. *Clin Chim Acta.* 1983; 131: 317-23.
139. Kawai Y, Anno K. Mucopolysaccharide -degrading enzymes from the liver of the squid, *Ommastrephes Sloani Pacificus*. I. Hyaluronidase. *Biochem Biophys Acta* 1971; 242: 428-36.
140. Rosenblit PD, Metzger RP, Wick AN. Effect of streptozotocin diabetes on acid phosphatase and selected glycosidase activities of serum and various rat organs. *Proc Soc Exp Biol Med.* 1974; 145: 244–48.
141. *Clinica Chimica Acta*, International Federation of clinical chemistry. 1980; 105: 145- 75.

142. Ajay M, Cheng HM, Mustafa AM, Mustafa MR. A comparative study on antioxidant activity of flavonoids: structure- activity relationships. *Malaysian J Sci.* 2005; 24(1): 187-90.
143. Kyaw A. Effect of starvation on lysosomal enzyme levels in mouse liver and peritoneal exudates. *Biochem Med.* 1978; 20: 7–14.
144. Tomboloni A, Cingolani M. Fatal accidental ingestion of carbon tetrachloride: a postmortem study. *J Forensic Sci.* 1996; 41: 166–68.
145. Wigglesworth JS. The use of osmium-ethyl gallate technique in the study of carbon tetrachloride liver injury. *J Path Bacteriol.* 1964; 87: 333–39.
146. Rubin E, Popper H. The evolution of human cirrhosis deduced from observations in experimental animals. *Medicine* 1967; 46: 163–83.
147. Kraehenbuehl S, Stucki J, Reichen J. Mitochondrial function in carbon tetrachloride-induced cirrhosis in the rat: quantitative and qualitative difference. *Biochem Pharmacol.* 1989; 38: 1583–88.
148. Younes M, Albrecht M, Siegers CP. Interrelation between lipid peroxidation and lysosomal enzyme release in the presence of carbon tetrachloride, cumene hydroperoxide or thioacetamide. *Res Commun Chem Pathol Pharmacol.* 1983; 40: 121–32.
149. Hultbergh B, Hagerstra, NI, Isaksson A. Source of increased serum hexosaminidase. *Enzyme.* 1988; 40: 18–24.

150. Harvey, Scanes CG. Effect of adrenaline and adrenergic active drugs on growth hormones secretions in an immature cockerels. Cellular and Mol Life sciences 1978; 34: 1096-97.
151. Panin LE, Maianaia NN, Klimenteva TK. The mechanism of action of hydrocortisone on the hepatic lysosomal apparatus. Probl Endokrinol. 1990; 36(1): 62-6.
152. Woo KJ, Jeong, YJ, Inoue, H, Park, JW and Kwon TK. Chrysin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression through the inhibition of nuclear factor for IL-6 (NF-IL6) DNA-binding activity. FEBS Letter. 2000; 579(3): 705-11.
153. Oka M, Morita K, Yoshizumi M, Houchi H, Ishimura Y, Masuda Y. Catecholamine secretion from adrenal chromaffin cells. Nippon Yakurigaku Zasshi 1991; 98 (3): 209-14